	US 11,685,774 B2
	Method of reducing blood glucose levels and inhibiting secreted aP2
Gokhan S. Hotamisligil, Wellesley, MA (US); and Haiming Cao, Bethesda, MD (US)
Assigned to President And Fellows of Harvard College, Cambridge, MA (US)
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
Filed on Nov. 23, 2020, as Appl. No. 17/102,329.
Application 17/102,329 is a continuation of application No. 15/851,040, filed on Dec. 21, 2017, granted, now 10,882,901.
Application 15/851,040 is a continuation of application No. 15/093,508, filed on Apr. 7, 2016, granted, now 9,879,078, issued on Jan. 30, 2018.
Application 15/093,508 is a continuation of application No. 13/203,880, abandoned, previously published as PCT/US2010/026305, filed on Mar. 5, 2010.
Claims priority of provisional application 61/299,170, filed on Jan. 28, 2010.
Claims priority of provisional application 61/209,251, filed on Mar. 5, 2009.
Prior Publication US 2021/0147527 A1, May 20, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); C07K 16/18 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01)]

6 Claims

1. A method of reducing blood glucose levels in a human comprising administering to the human an effective amount of an Adipocyte Protein 2 (aP2)-specific antibody that specifically binds to aP2 in blood or serum.